Get the Stockscreener App
13.52
2.17%
-0.30
After Hours:
13.52
Tyra Biosciences Inc stock is traded at $13.52, with a volume of 161.43K.
It is down -2.17% in the last 24 hours and up +13.52% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$13.82
Open:
$13.87
24h Volume:
161.43K
Relative Volume:
0.78
Market Cap:
$720.58M
Revenue:
-
Net Income/Loss:
$-83.74M
P/E Ratio:
-8.3975
EPS:
-1.61
Net Cash Flow:
$-64.98M
1W Performance:
-1.02%
1M Performance:
+13.52%
6M Performance:
+79.07%
1Y Performance:
-35.56%
1-Day Range:
$13.29
$13.91
1-Week Range:
$12.98
$13.98
52-Week Range:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
13.52 | 736.57M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Will Tyra Biosciences Inc. continue its uptrendForecast Cut & Technical Pattern Recognition Alerts - newser.com
Using Python tools to backtest Tyra Biosciences Inc. strategiesQuarterly Portfolio Report & Long-Term Safe Return Strategies - newser.com
Combining machine learning predictions for Tyra Biosciences Inc.Quarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Is now a turning point for Tyra Biosciences Inc.July 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
How to build a custom watchlist for Tyra Biosciences Inc.July 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Backtesting results for Tyra Biosciences Inc. trading strategiesMarket Rally & Reliable Breakout Forecasts - newser.com
Will Tyra Biosciences Inc. stock benefit from automation2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Why retail investors favor Tyra Biosciences Inc. stockJuly 2025 Movers & Safe Capital Growth Trade Ideas - newser.com
Tyra Biosciences' (TYRA) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Tyra Biosciences Inc (TYRA): What is the Risk Factor? - fostersleader.com
Tyra Biosciences Inc. stock daily chart insightsQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
Can Tyra Biosciences Inc. stock withstand economic slowdownShort Setup & Real-Time Market Trend Scan - newser.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Public Employees Retirement System of Ohio Takes Position in Tyra Biosciences, Inc. $TYRA - Defense World
Real time scanner hits for Tyra Biosciences Inc. explainedTrade Volume Summary & Long-Term Growth Plans - newser.com
Is Tyra Biosciences Inc. stock ready for a breakoutQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
Tyra Biosciences Inc.’s volatility index tracking explainedJuly 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Tyra Biosciences (NASDAQ:TYRA) Raised to "Hold" at Wall Street Zen - MarketBeat
Is Tyra Biosciences Inc. stock affected by interest rate hikes2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? - MSN
Will Tyra Biosciences Inc. stock reach Wall Street targetsWeekly Market Report & Daily Chart Pattern Signals - newser.com
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth - Sahm
Non Muscle Invasive Bladder Cancer Pipeline 2025: Pioneering - openPR.com
Tyra Biosciences, Inc. $TYRA Shares Sold by Canaan Partners XI LLC - MarketBeat
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tyra Biosciences Inc Stock (TYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Jun 17 '25 |
Sale |
10.35 |
10 |
104 |
37,799 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):